Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs

Expert Review of Anti-Infective Therapy

Volumn 16, Issue 6, 2018, Pages 501-512

  Goletti, Delia ^a   Petrone, Linda ^a   Ippolito, Giuseppe ^a   Niccoli, Laura ^b   Nannini, Carlotta ^b   Cantini, Fabrizio ^b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b Hospital of Prato   (Italy)

Author keywords

IGRA; latent tuberculosis infection; preventive therapy; rheumatoid arthritis; rheumatological diseases; therapy; TST; Tuberculosis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANAKINRA; BIOLOGICAL PRODUCT; BRENZYS; CERTOLIZUMAB PEGOL; CT P 13; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ISONIAZID; IXEKIZUMAB; RIFAMPICIN; RIFAPENTINE; RITUXIMAB; SB 4; SECUKINUMAB; TOCILIZUMAB; TUBERCULOSTATIC AGENT; USTEKINUMAB; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR;

ANTIBIOTIC THERAPY; COMORBIDITY; HUMAN; INCIDENCE; INFECTION RISK; LATENT TUBERCULOSIS; NONHUMAN; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TUBERCULOSIS CONTROL; ANTAGONISTS AND INHIBITORS; MASS SCREENING; PROCEDURES; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; BIOLOGICAL PRODUCTS; HUMANS; LATENT TUBERCULOSIS; MASS SCREENING; RHEUMATIC DISEASES; RISK FACTORS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85049839812     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2018.1483238     Document Type: Review

References (140)

1. WHO. TB REPORT. [cited 2018 Feb 7]. Available from: http://apps.who.int/iris/bitstream/handle/10665/259366/9789241565516-eng.pdf?sequence=1. (2017)
2. Houben RM, Dodd PJ., The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152
3. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against mycobacterium tuberculosis in mice. Immunity. 1995;2(6):561–572
4. Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076
5. Fox GJ, Barry SE, Britton WJ, et al. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2013;41(1):140–156
6. Antonucci G, Girardi E, Raviglione MC, et al. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA. 1995;274(2):143–148
7. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368–2376
8. Dobler CC, McDonald SP, Marks GB. Risk of tuberculosis in dialysis patients: a nationwide cohort study. PLoS One. 2011;6(12):e29563
9. ESCMID Study Group of Infection in Compromised Hosts, Meije Y, Piersimoni C, Torre-cisneros J, et al. Mycobacterial infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(Suppl 7):89–101
10. Ergun I, Ekmekci Y, Sengul S, et al. Mycobacterium tuberculosis infection in renal transplant recipients. Transplant Proc. 2006;38(5):1344–1345
11. Akan H, Arslan O, Akan OA. Tuberculosis in stem cell transplant patients. J Hosp Infect. 2006;62(4):421–426
12. Leung CC, Yu IT, Chen W. Silicosis. Lancet. 2012;379(9830):2008–2018
13. Corbett EL, Churchyard GJ, Clayton TC, et al. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS. 2000;14(17):2759–2768
14. Meredith S, Watson JM, Citron KM, et al. Are healthcare workers in England and Wales at increased risk of tuberculosis? BMJ. 1996;313(7056):522–525
15. Chu H, Shih CJ, Lee YJ, et al. Risk of tuberculosis among healthcare workers in an intermediate-burden country: a nationwide population study. J Infect. 2014;69(6):525–532
16. Jo KW, Woo JH, Hong Y, et al. Incidence of tuberculosis among health care workers at a private university hospital in South Korea. Int J Tuberc Lung Dis. 2008;12(4):436–440
17. Marks GB, Bai J, Simpson SE, et al. Incidence of tuberculosis among a cohort of tuberculin-positive refugees in Australia: reappraising the estimates of risk. Am J Respir Crit Care Med. 2000;162(5):1851–1854
18. Wobeser WL, Yuan L, Naus M, et al. Expanding the epidemiologic profile: risk factors for active tuberculosis in people immigrating to Ontario. CMAJ. 2000;163(7):823–828
19. Wong J, Lowenthal P, Flood J, et al. Increased tuberculosis risk among immigrants arriving in California with abnormal domestic chest radiographs. Int J Tuberc Lung Dis. 2018;22(1):73–79
20. Getahun H, Baddeley A, Raviglione M. Managing tuberculosis in people who use and inject illicit drugs. Bull World Health Organ. 2013;91(2):154–156
21. Goletti D, Sanduzzi A, Delogu G. Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol Suppl. 2014;91:24–31
22. Delogu G, Goletti D. The spectrum of tuberculosis infection: new perspectives in the era of biologics. J Rheumatol Suppl. 2014;91:11–16
23. Petruccioli E, Scriba TJ, Petrone L, et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J. 2016;48(6):1751–1763
24. Mahairas GG, Sabo PJ, Hickey MJ, et al. Molecular analysis of genetic differences between mycobacterium bovis BCG and virulent M. bovis. J Bacteriol. 1996;178(5):1274–1282
25. Andersen P, Munk ME, Pollock JM, et al. Specific immune-based diagnosis of tuberculosis. Lancet. 2000;356(9235):1099–1104
26. Barcellini L, Borroni E, Brown J, et al. First evaluation of quantiFERON-TB gold plus performance in contact screening. Eur Respir J. 2016;47:1587–1590
27. Petruccioli E, Chiacchio T, Pepponi I, et al. First characterization of the CD4 and CD8 T-cell responses to quantiFERON-TB plus. J Infect. 2016;73:588–597
28. Petruccioli E, Vanini V, Chiacchio T, et al. Analytical evaluation of quantiFERON- plus and quantiFERON- gold in-tube assays in subjects with or without tuberculosis. Tuberculosis (Edinb). 2017;106:38–43
29. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med. 2004;170(1):59–64
30. Chiacchio T, Petruccioli E, Vanini V, et al. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. J Infect. 2014;69:533–545
31. Day CL, Abrahams DA, Lerumo L et al. Functional capacity of mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol. 2011;187(5):2222–2232
32. Rozot V, Patrizia A, Vigano S, et al. Combined use of mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosis. Clin Infect Dis. 2015;60(3):432–437
33. Ruhwald M, Aggerbeck H, Gallardo RV, et al. Safety and efficacy of the C-Tb skin test to diagnose mycobacterium tuberculosis infection, compared with an interferon gamma release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. Lancet Respir Med. 2017;5(4):259–268
34. Getahun H, Chaisson RE, Raviglione M. Latent mycobacterium tuberculosis infection. N Engl J Med. 2015;373(12):1179–1180
35. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52(6):1766–1772
36. Goletti D, Vincenti D, Carrara S, et al. Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. Clin Diagn Lab Immunol. 2005;12(11):1311–1316
37. So H, Yuen CS, Yip RM. Comparison of a commercial interferon-gamma release assay and tuberculin skin test for the detection of latent tuberculosis infection in Hong Kong arthritis patients who are candidates for biologic agents. Hong Kong Med J. 2017;23(3):246–250
38. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36(5):1185–1206
39. Bartalesi F, Vicidomini S, Goletti D, et al. QuantiFERON-TB gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J. 2009;33(3):586–593
40. Goletti D, Petruccioli E, Joosten SA, et al. Tuberculosis biomarkers: from diagnosis to protection. Infect Dis Rep. 2016;8(2):6568
41. Smith R, Cattamanchi A, Steingart KR, et al. Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol. 2011;23(4):377–384
42. Pai M, Joshi R, Dogra S, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis. 2009;13(1):84–92
43. Bartalesi F, Goletti D, Spinicci M, et al. Serial quantiFERON TB-gold in-tube testing during LTBI therapy in candidates for TNFi treatment. J Infect. 2013;66(4):346–356
44. Johnson MG, Bialas RW, Hall RP, et al. Should all patients undergoing treatment with biologic agents be screened annually for latent tuberculosis infection with an interferon gamma release assay? J Dermatolog Treat. 2016;27(4):378–380
45. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45–55
46. Zellweger JP, Sotgiu G, Block M, et al. Risk assessment of tuberculosis in contacts by IFN-gamma release assays. a tuberculosis network European Trials Group study. Am J Respir Crit Care Med. 2015;191(10):1176–1184
47. Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 2016;387:2312–2322
48. Kik SV, Cobelens F, Moore D. Predicting tuberculosis risk. Lancet. 2016;388(10057): 2233–6736. (16)32070-0
49. Maertzdorf J, Repsilber D, Parida SK, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun. 2011;12(1):15–22
50. Sweeney TE, Braviak L, Tato CM, et al. Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis. Lancet Respir Med. 2016;4(3):213–224
51. Butera O, Chiacchio T, Carrara S, et al. New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. BMC Infect Dis. 2009;9:182
52. De Paus RA, Van Meijgaarden KE, Prins C, et al. Immunological characterization of latent tuberculosis infection in a low endemic country. Tuberculosis (Edinb). 2017;106:62–72
53. Chiacchio T, Delogu G, Vanini V, et al. Immune characterization of the HBHA-specific response in mycobacterium tuberculosis-infected patients with or without HIV infection. PLoS One. 2017;12(8):e0183846
54. Delogu G, Chiacchio T, Vanini V, et al. Methylated HBHA produced in M. smegmatis discriminates between active and non-active tuberculosis disease among RD1-responders. PLoS One. 2011;6(3):e18315
55. Delogu G, Vanini V, Cuzzi G, et al. Lack of response to HBHA in HIV-infected patients with latent tuberculosis infection. Scand J Immunol. 2016;84:344–352
56. Goletti D, Butera O, Vanini V, et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J. 2010;36(1):135–142
57. Leyten EM, Arend SM, Prins C, et al. Discrepancy between mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol. 2007;14(7):880–885
58. Black GF, Thiel BA, Ota MO, et al. Immunogenicity of novel dosR regulon-encoded candidate antigens of mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol. 2009;16(8):1203–1212
59. Elyoussfi S, Thomas BJ, Ciurtin C. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. Rheumatol Int. 2016;36(5):603–612
60. Nam JL, Takase-Minegishi K, Ramiro S, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1113–1136
61. Sieper J. New treatment targets for axial spondyloarthritis. Rheumatology (Oxford). 2016;55(suppl 2):ii38–ii42
62. European Medicines Agency. EMA/CHMP/589317/2013 Committee for Medicinal Products for Human Use (CHMP). Procedure No. EMEA/H/C/002576/0000. Remsima assessment report
63. European Medicines Agency. EMA/CHMP/819219/2015 Committee for Medicinal Products for Human Use (CHMP). Procedure No. EMEA/H/C/004007/0000 Benepali assessment report
64. Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14(6):503–509
65. Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-alpha antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(3):e012567. 2016-012567
66. Watanabe A, Matsumoto T, Igari H, et al. Risk of developing active tuberculosis in rheumatoid arthritis patients on adalimumab in Japan. Int J Tuberc Lung Dis. 2016;20(1):101–108
67. Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-alpha (TNF-alpha) targeted biologics and recently licensed TNF-alpha inhibitors: data from clinical trials and national registries. J Rheumatol Suppl. 2014;91:56–64
68. Cantini F, Nannini C, Niccoli L, et al. Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics. Mediators Inflamm. 2017;2017:8909834
69. Baddley JW, Cantini F, Goletti D, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumour necrosis factor-α agents). Clin Microbiol Infect. 2018;24:S10-S20
70. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–1104
71. Mohan AK, Cote TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004;39(3):295–299
72. Jensen PA, Lambert LA, Iademarco MF, et al. CDC. Guidelines for preventing the transmission of mycobacterium tuberculosis in health-care settings. MMWR Recomm Rep. 2005;54(RR–17):1–141
73. Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology. 2010;15(4):603–622
74. Carmona L, Hernandez-Garcia C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol. 2003;30(7):1436–1439
75. Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007;34(4):706–711
76. Brassard P, Lowe AM, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum. 2009;61(3):300–304
77. Cantini F, Goletti D. Biologics and tuberculosis risk: the rise and fall of an old disease and its new resurgence. J Rheumatol Suppl. 2014;91:1–3
78. Hsia EC, Cush JJ, Matteson EL, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in phase III clinical trials. Arthritis Care Res (Hoboken). 2013;65(2):309–313
79. Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis. 2015;74(1):96–103
80. Van Der Heijde D, Dougados M, Landewe R, et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford). 2017;56(9):1498–1509
81. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48–55
82. Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15(12):1677–1683
83. Esmail H, Wilkinson RJ. Minimizing tuberculosis risk in patients receiving anti-TNF therapy. Ann Am Thorac Soc. 2017;14(5):621–623
84. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52(7):1986–1992
85. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006;43(6):717–722
86. Biobadaser Group, Jj G-R, Carmona L, Angel DM. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57(5):756–761
87. Favalli EG, Desiati F, Atzeni F, et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009;8(3):266–273
88. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum. 2009;60(7):1884–1894
89. Kim EM, Uhm WS, Bae SC, et al. Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol. 2011;38(10):2218–2223
90. Ventura-Rios L, Banuelos-Ramirez D, Hernandez-Quiroz Mdel C, et al. Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0. Reumatol Clin. 2012;8(4):189–194
91. Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012;12(2):225–229
92. Alawneh KM, Ayesh MH, Khassawneh BY, et al. Anti-TNF therapy in Jordan: a focus on severe infections and tuberculosis. Biologics. 2014;8:193–198
93. Harrold LR, Litman HJ, Saunders KC, et al. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry. Arthritis Res Ther. 2018;20(1):2–017-1496–5
94. Cuomo G, D’Abrosca V, Iacono D, et al. The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis. Clin Rheumatol. 2017;36(2):457–461
95. Scrivo R, Sauzullo I, Mengoni F, et al. The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature. Clin Rheumatol. 2016;35(5):1383–1388
96. Sauzullo I, Mengoni F, Marocco R, et al. Interferon-gamma release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis. Br J Dermatol. 2013;169(5):1133–1140
97. Hatzara C, Hadziyannis E, Kandili A, et al. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis. 2015;74(10):1848–1853
98. Banaei N, Gaur RL, Pai M. Interferon gamma release assays for latent tuberculosis: what are the sources of variability? J Clin Microbiol. 2016;54(4):845–850
99. Edwards A, Gao Y, Allan RN, et al. Corticosteroids and infliximab impair the performance of interferon-gamma release assays used for diagnosis of latent tuberculosis. Thorax. 2017;72(10):946–949
100. Son CN, Jun JB, Kim JH, et al. Follow-up testing of interferon-gamma release assays are useful in ankylosing spondylitis patients receiving anti-tumor necrosis factor alpha for latent tuberculosis infection. J Korean Med Sci. 2014;29(8):1090–1093
101. Hsiao C-Y, Chiu H-Y, Wang T-S, et al. Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab. PLoS One. 2017;12(9):e0184178
102. Chen YM, Chen HH, Lai KL, et al. The effects of rituximab therapy on released interferon-gamma levels in the quantiFERON assay among RA patients with different status of mycobacterium tuberculosis infection. Rheumatology (Oxford). 2013;52(4):697–704
103. Kammüller M, Tsai T-F, Griffiths CE, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased mycobacterium tuberculosis infections. Clin Translational Immunol. 2017;6(8):e152
104. Scrivo R, Sauzullo I, Mengoni F, et al. Mycobacterial interferon-gamma release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome. J Rheumatol. 2013;40(2):157–165
105. Chen DY, Li JP, Chen YM, et al. Elevated neopterin levels are associated with increased tuberculosis risk in rheumatoid arthritis patients with quantiFERON conversion during biologic therapy. PLoS One. 2016;11(11):e0166301
106. Coates LC, Kishimoto M, Gottlieb A, et al. Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naive patients with active psoriatic arthritis (PsA): results from SPIRIT-P1. RMD Open. 2017;3(2):e000567. 2017-000567.eCollection
107. Souto A, Maneiro JR, Salgado E, et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014;53(10):1872–1885
108. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403–3412
109. BIOBADASER Group, Jj G-R, Carmona L, Vr V, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48(8):2122–2127
110. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69(3):522–528
111. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189–194
112. Yonekura CL, Oliveira RDR, Titton DC, et al. Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian registry of biological therapies in rheumatic diseases (registro brasileiro de monitoracao de terapias biologicas - biobadaBrasil). Rev Bras Reumatol Engl Ed. 2017;57(Suppl 2):477–483
113. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21(4):343–351
114. BSRBR Control Centre Consortium, Hyrich K, Symmons D, Watson K, et al. British Society for Rheumatology Biologics Register. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis. 2006;65(7):895–898
115. Husted JA, Thavaneswaran A, Chandran V, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken). 2011;63(12):1729–1735
116. Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55(1):19–26
117. British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee, Milburn H, Ashman N, et al. Guidelines for the prevention and management of mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax. 2010;65(6):557–570
118. Lim CH, Chen HH, Chen YH, et al. The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: a 15-year real world experience in Taiwan. PLoS One. 2017;12(6):e0178035
119. Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013;72(1):37–42
120. Li J, Chung PH, Leung CLK, et al. The strategic framework of tuberculosis control and prevention in the elderly: a scoping review towards End TB targets. Infect Dis Poverty. 2017;6(1):70
121. WHO. Guidelines on the management of latent tuberculosis infection. 2015. p. 6–10. Available from: http://apps.who.int/iris/bitstream/handle/10665/136471/9789241548908_eng.pdf?sequence=1
122. Tr S, Me V, As B, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–2166
123. Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000;2(2):CD001363
124. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149(10):689–697
125. Adamu B, Abdu A, Abba AA, et al. Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis. Cochrane Database Syst Rev. 2014;4:CD008597
126. Falk A, Fuchs GF. Prophylaxis with isoniazid in inactive tuberculosis. A veterans administration cooperative study XII. Chest. 1978;73(1):44–48
127. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International union against tuberculosis committee on prophylaxis. Bull World Health Organ. 1982;60(4):555–564
128. De S, Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA. 1986;255(12):1579–1583
129. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281(11):1014–1018
130. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med. 2003;168(4):443–447
131. Fox GJ, Dobler CC, Marais BJ, et al. Preventive therapy for latent tuberculosis infection-the promise and the challenges. Int J Infect Dis. 2017;56:68–76
132. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS board of directors, July 1999. This is a joint statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161(4Pt 2):S221–47
133. Stagg HR, Zenner D, Harris RJ, et al. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161(6):419–428
134. Menzies D. Randomized clinical trial comparing 4RIF vs. 9INH for LTBI treatment-effectiveness. 2016.NCT00931736
135. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005;40(5):670–676
136. Hanta I, Ozbek S, Kuleci S, et al. Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha. Clin Rheumatol. 2007;26(11):1867–1870
137. Cansu DU, Guncan S, Bilge NS, et al. Does isoniazid chemoprophylaxis increase the frequency of hepatotoxicity in patients receiving anti-TNF-alpha agent with a disease-modifying antirheumatic drug? Eur J Rheumatol. 2014;1(2):62–66
138. Bray MG, Poulain C, Dougados M, et al. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment. Joint Bone Spine. 2010;77(2):135–141
139. Winthrop KL, Mariette X, Silva JT, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24:S21–S40
140. Goletti D, Lee MR, Wang JY, et al. Update on tuberculosis biomarkers: from correlates of risk, to correlates of active disease and of cure from disease. Respirology. 2018;23(5):455–466